Seeking Alpha


Send Message
View as an RSS Feed
View listech's Comments BY TICKER:
Latest  |  Highest rated
  • Questcor - Let's Compare Numbers [View article]
    Thanks Brian. Nicely done analysis.
    I have had Q in my portfolio for more than 3 years now and although frustrating sometimes because of all the noise surrounding it, it has proven to be a solid investment for me. As far as it going to $100, $115, or $120, especially in the next 12-14 months well, "from their mouths to God's ear!"
    I have been told that at their last National Sales meeting, Bailey shared openly that some acquisition, merger or new application news was forthcoming. Now that will bump this s/p regardless of the analytics! Never discount the psychology of the marketplace and the impact good news has on valuation.
    Anyway, here's wishing all longs well...
    Mar 6, 2014. 10:45 AM | 7 Likes Like |Link to Comment
  • PT hike an excuse to take profits in Galena [View news story]
    I'm struggling with making a decision on AMRN. When they hit the wall with the FDA last month, I decided to hold on to a relatively nice portfolio of AMRN that I felt would come back so instead of taking the loss and using the $ elsewhere, I held on. It looks like that may have been a mistake or at least a very long term investment.

    We all know the details and how this will probably work but does anyone have a feel for what AMRN may be thinking will be their next move? Is there a near-term possibility they may bail or is there any rumor of a sale to someone.

    I just can't seem to find any information on what may be in store. They seemed to have dropped off the face of the earth!
    Jan 28, 2014. 11:17 AM | Likes Like |Link to Comment
  • PT hike an excuse to take profits in Galena [View news story]

    Well-loved? Come on. AF probably knows more about Biotech stocks than I do because I have a real job to go to everyday and can't spend 12 hours a day on research but, he's not well-loved! And Cramer is just a fast-talking con artist whose opinions can no longer be trusted...Sorry, very little sleep last night!
    Jan 28, 2014. 11:06 AM | Likes Like |Link to Comment
  • Get set for capital raise at Amarin after ANCHOR SPA rejection [View news story]
    Sadly, this is a company that appeared to do everything right but apparently didn't calculate the impact of the FDA's decision-making power.
    Too many people get caught up in how good it was and "how it couldn't lose". Not real good business-decision thinking and I was one of them! It's classic stock trader's wishful thinking!

    Learn by our mistakes and never make them again and we'll be ahead of the game!
    Jan 21, 2014. 12:11 PM | 2 Likes Like |Link to Comment
  • PT hike an excuse to take profits in Galena [View news story]
    It's obviously tempting for someone not in it for the long run and not interested in what the company really has to offer in Oncology, to bail out and take a short run profit when clowns like Cramer say "run"!
    This is a good longer term investment that's still very affordable so rheimerl is right ... relax!
    Jan 21, 2014. 12:03 PM | 5 Likes Like |Link to Comment
  • Rexahn Pharma slides after announcing offering [View news story]
    Hey, if I really wanted to look at some of my stupid decisions and bad timing, there are dozens of them, REGN, QCOR and so many more. I don't lose too much sleep over them anymore!
    Best of luck in all your trades!
    Jan 21, 2014. 11:19 AM | Likes Like |Link to Comment
  • Rexahn Pharma slides after announcing offering [View news story]
    Agree Joe Kelly. This is a good little company and at these prices is a good speculative offer. I'm buying more today too if the price holds at around $1.00 but there will be plenty of opportunities to buy low and sell when it takes off on good news. I made a lot of $ doing this with GALE in their early days.
    The real payoff is in the future and that will require a real long mentality.
    Jan 16, 2014. 10:15 AM | Likes Like |Link to Comment
  • Rexahn Pharma slides after announcing offering [View news story]
    Amen to that!
    Jan 15, 2014. 11:06 AM | Likes Like |Link to Comment
  • Questcor Pharmaceuticals' CEO Presents at Oppenheimer 24th Annual Healthcare Conference (Transcript) [View article]
    I've held this stock for years now and all I've ever read is it's "undervalued" and to stay long! How can this stock have the dramatic fluctuations it has had consistantly and yet have the amazing numbers it posts every earning quarter. And each time Citron raises their ugly head and manipulates the price, management reminds us of the dividend; buys back shares and talks about other indications! It had a great run up; I stayed loyal again hoping for the big hit up to $80 (like all the experts always predict) and then it falls like a rock and I have to wait for it to climb $10 just so I can break even. I'm really tired of it!
    Dec 12, 2013. 11:25 AM | 2 Likes Like |Link to Comment
  • Questcor Pharmaceuticals (QCOR) is "experiencing solid uptake" of its Acthar Gel in the area of rheumatology, including "a larger than expected number of prescriptions for rheumatoid arthritis." Qestcor now intends to accelerate its plans for a pilot commercialization of Acthar for patients who suffer respiratory problems from the autoimmune disease symptomatic sarcoidosis. Questcor plans to hire a sales team of 5-10 people and begin contacting pulmonologists in Q4. The company is also evaluating potential clinical studies that have been proposed by key opinion leaders in the field of sarcoidosis. (PR[View news story]
    I'm pretty close to what's happening in this company and I can tell you with certainty that management is slowly but seriously investigating the release of all of those indications for which they have already been approved. The R.A. venture is the first of many. The most profitable one and the one that will put them on the map will be NS -- a huge market! They are already talking about the sales force for that one. I'm long on QCOR and think it's going to be a real winner!
    Jul 11, 2013. 10:07 AM | Likes Like |Link to Comment
  • Shares of Arena Pharmaceuticals (ARNA -6.8%) dip on disappointing Belviq script data. According to TheStreet's Adam Feuerstein, Belviq TRx for week of June 21st were just 1,829, citing IMS. For the week of June 14th they were 1,087. [View news story]
    Adam, you dope! At least give a plausible rationale for your stupid comments!
    Jul 1, 2013. 10:46 AM | Likes Like |Link to Comment
  • Galena Biopharma (GALE -4.3%) gives a pipeline update at ASCO, saying that NeuVax continues to demonstrate "durable response rates", and that a companion diagnostic for HER2 screening in women with breast cancer "increases accuracy." It also reported positive results from Phase 1/2a studies of its folate binding protein, HLA-A2, a restricted peptide immunotherapy for treating ovarian and endometrial cancer. [View news story]
    Agree, Michael. Can't see any other reason for drop.
    Jun 4, 2013. 10:31 AM | Likes Like |Link to Comment
  • In its call earlier, Dendreon (DNDN -12%) CEO John Johnson attributed its big Q1 miss on Provenge sales to increased competition, with the hit coming hardest in its smaller accounts which are less experienced with injectable therapies like DNDN's. But the veracity in today's selloff may be more closely linked to DNDN's sizeable chunk of convertible notes expiring in 2014 and 2016. Without any real operating income, Seeking Alpha contributor Brian Wilson thinks shareholders are facing some massive dilution on the horizon. (Webcast). [View news story]
    I sold my position at $5.98 some time ago. I was hoping to get back in but that is looking less and less likely. Saddest part is that Provenge may have saved lives.
    May 13, 2013. 12:10 PM | Likes Like |Link to Comment
  • Amarin (AMRN -0.6%) lags the general market after being being given a less than enthusiastic initiation by analysts at Chardan Capital Markets with a Hold rating and a price target of $8.50 a share. The firm says that the chance for a strategic deal over the near-term is low, and Vascepa faces risks of a tepid debut. [View news story]
    Amen, drrc1949!
    AMRN is going to be a winner but they need to get out there and sell the story and who cares what the analysts say. They're never right anyway!
    Mar 21, 2013. 11:42 AM | Likes Like |Link to Comment
  • Questcor Drops On Headline Misunderstanding [View article]
    And here we go again! This time its "Oh my, an error!" Let's sit back and watch this terribly under-valued stock be manipulated again by these thieves!

    I have always been long on QCOR because I know the value of what they have and the great potential they have but to be quite honest, I'm getting real tired of tying up so much of my investing capital in a stock so easily manipulated and controlled. I've been investing in it for almost 2 years now and I'm still under water! Truthfully, I'm getting ready to bail, sell for some tax loses in 2012 and limit my position going forward...I'm just sick of the insecurity of it all despite the great numbers that apparently mean nothing!

    Am I alone in feeling this way or not?
    Nov 2, 2012. 01:03 PM | Likes Like |Link to Comment